For many patients with invasive bladder cancer, regional or systemic metastases are present at the time of presentation. Owing to the risk of micrometastatic disease, preoperative neoadjuvant cisplatin-based chemotherapy before radical cystectomy or radiation has been assessed and shown to provide a survival advantage.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bochner, B. H. et al. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J. Clin. Oncol. 24, 3967–3972 (2006).
Griffiths, G. et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171–2177 (2011).
International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomized controlled trial. Lancet 354, 533–540 (1999).
Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859–866 (2003).
Arriagada, R. et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N. Engl. J. Med. 350, 351–360 (2004).
Schrag, D. et al. Cystectomy for muscle-invasive bladder cancer: patterns and outcomes of care in the Medicare population. Urology 65, 1118–1125 (2005).
David, K. A., Milowsky, M. I., Ritchey, J., Carroll, P. R. & Nanus, D. M. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J. Urol. 178, 451–454 (2007).
Feifer, A. et al. Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: phase I [abstract]. J. Clin. Oncol. 29 (Suppl. 7), a240 (2011).
Canter, D. et al. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int. 107, 58–62 (2011).
Vale, C. L. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur. Urol. 48, 189–199 (2005).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Bochner, B. Standardizing the care of invasive bladder cancer. Nat Rev Clin Oncol 8, 454–455 (2011). https://doi.org/10.1038/nrclinonc.2011.109
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.109
